Uric Acid-Binding Polymers for Lower-Side-Effect Hyperuricemia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for gout and hyperuricemia, such as colchicine, are ineffective for many individuals due to severe side effects, and there is a need for new drugs to lower uric acid levels and treat conditions caused by hyperuricemia.
Innovation Solution
Development of polymers, such as grafted polytriallylamine, which bind to uric acid or its precursors, providing a medicament for treating and preventing gout, hyperuricemia, and associated diseases, with potential benefits for coronary heart disease prevention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If colchicine is administered orally to treat gout, then the treatment effectiveness is improved, but side effects increase significantly
Solution Approach 1:
The patent uses polytriallylamine and its grafted derivatives as intermediary substances that bind to uric acid in the gastrointestinal tract, preventing its absorption into the bloodstream. This mediator approach avoids the need for colchicine that causes severe side effects, while still achieving the therapeutic goal of lowering uric acid levels through a different mechanism of action.
Solution Approach 2:
The invention extracts and removes uric acid from the gastrointestinal tract before it can be absorbed systemically. By using polymer-based binders that specifically capture uric acid in the gut, the treatment eliminates the harmful substance through fecal excretion rather than requiring systemic pharmacological intervention that causes side effects.
2Ease of operation
If conventional gout treatments are used, then some patients experience symptom relief, but 80 percent of people cannot tolerate the treatment due to side effects
Solution Approach 1:
The patent employs disposable polymer binders that are administered orally and work locally in the gastrointestinal tract. These short-acting binders are excreted in feces along with bound uric acid, providing a temporary but effective treatment that can be repeated as needed without accumulating in the body or causing systemic toxicity.
Solution Approach 2:
The polymer compounds serve as intermediary agents that facilitate uric acid removal without requiring the patient to tolerate colchicine's side effects. The mediator approach allows treatment of the underlying hyperuricemia condition while avoiding the toxic effects of conventional gout medications.
3Quantity of substance
If existing uric acid lowering drugs are administered, then serum uric acid levels decrease, but severe side effects limit their use in the majority of patients
Solution Approach 1:
The patent converts the previously harmful approach of systemically inhibiting uric acid production or excretion into a beneficial local action in the gastrointestinal tract. By binding uric acid in the gut and promoting its excretion, the treatment achieves uric acid lowering without the metabolic side effects of xanthine oxidase inhibitors or uricosurics.
Solution Approach 2:
The polytriallylamine derivatives act as intermediary substances that facilitate uric acid removal through a benign mechanism. These mediators bind uric acid in the gastrointestinal tract and promote its excretion without interfering with normal metabolic processes, thereby avoiding the side effects associated with conventional uric acid lowering drugs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymers effectively bind uric acid, lowering serum levels and treating conditions like gout and hyperuricemia, offering a safer alternative to existing treatments.
Implementation Method 1
The polymers effectively bind uric acid, lowering serum levels
Data Source
AI summary
The disclosure provides small molecule compounds, polymers, and compositions thereof, as well as methods for preparing such polymers and compositions. Also provided is a method of using the polymers or compositions thereof for binding uric acid or precursor thereof, and/or for treating hyperuricemia, gout, and/or diseases caused by hyperuricemia.